Clorox, Fortune Brands, and More Had Insiders Buy Shares

Page 1 of 2

Sales of stock by insiders can indicate that the insiders are negative about the company’s prospects, but not always; it is rational to diversify, and if an insider already depends on a company for a portion of their income it can make sense to sell even if they have neutral feelings about the stock. Purchases by insiders are another story. The same logic explaining why insiders might sell even if they aren’t bearish on the stock should prevent insiders from buying- unless, of course, they are so confident that the company is going to beat expectations that it’s worth giving up diversification. This is one explanation for why insider purchases, on average, beat the market. Read more about studies on insider trading. We have gone through our database of insider trading filings and here are five stocks that insiders have bought recently:

A senior Vice President at Health Management Associates, Inc. (NYSE:HMA) bought 10,000 shares at an average price of $7.76. The $2.1 billion market cap hospital operator is smaller than peers such as HCA Holdings (NYSE:HCA), and the market seems to be depending on the company to grow faster than other companies in the industry. The forward P/E is 9- even with HCA’s- but the trailing P/E is 14 and earnings have actually been down to flat in recent quarters. Larry Robbins’ Glenview Capital was a major investor in both of these hospital stocks during the third quarter (see more stock picks from Larry Robbins); as for ourselves, we think that we’d lean towards HCA.


Multiple insiders have been buying shares of women’s retailer Francesca’s Holdings Corp (NASDAQ:FRAN), including the president and the CEO. Consensus buying by insiders is a particularly bullish signal (learn more about consensus insider purchases), at least on average. The company has been reporting strong financials, with revenue up 43% in the third quarter compared to a year ago and net income doubling. However, the valuation already captures significant future growth given the trailing P/E of 26. It’s also widely shorted, and we think that we might avoid it.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!